P53 codon 72 polymorphism contributes to breast cancer risk: A meta-analysis based on 39 case-control studies

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 509-517

  Zhang, Zhizhong ^a   Wang, Meilin ^a   Wu, Dongmei ^a   Wang, Miaomiao ^a   Tong, Na ^a   Tian, Yuanyuan ^a   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Genetic variation; Meta analysis; Molecular epidemiology; P53

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CASE CONTROL STUDY; CODON; ETHNICITY; EUROPE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950689604     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0480-4     Document Type: Article

References (55)

1. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156 (Pubitemid 32911406)
2. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270-282
3. Veronesi U, Boyle P, Goldhirsch A et al (2005) Breast cancer. Lancet 365:1727-1741
4. Bartkova J, Lukas J, Strauss M et al (1995) Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778
5. 5. Porter-Jordan K, Lippman ME (1994) Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 8: 73-100 (Pubitemid 24086154)
6. Callahan R, Cropp CS, Merlo GR et al (1992) Somatic mutations and human breast cancer. A status report. Cancer 69:1582-1588
7. Hollstein M, Sidransky D, Vogelstein B et al (1991) p53 mutations in human cancers, Science 253:49-53
8. 8. Petitjean A, Achatz MI, Borresen-Dale AL et al (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165 (Pubitemid 46536647)
9. 9. Harris N, Brill E, Shohat O et al (1986) Molecular basis for heterogeneity of the human p53 protein. MoI Cell Biol 6:4650-4656 (Pubitemid 17217402)
10. 10. Dumont P, Leu JI, Delia Pietra ACIII et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365 (Pubitemid 36278852)
11. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
13. Egger M, Davey Smith G, Schneider M et al (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634
14. 14. Kawajiri K, Nakachi K, Imai K et al (1993) Germ line polymorphisms of p53 and CYPlAl genes involved in human lung cancer. Carcinogenesis 14:1085-1089 (Pubitemid 23193532)
15. 15. Sjalander A, Birgander R, Hallmans G et al (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313-1316 (Pubitemid 26196343)
16. 16. Weston A, Pan CF, Ksieski HB et al (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105-112 (Pubitemid 27069203)
17. 17. Wang-Gohrke S, Rebbeck TR, Besenfelder W et al (1998) p53 germline polymorphisms are associated with an increased risk for breast cancer in German, women. Anticancer Res 18:2095-2099 (Pubitemid 28344879)
18. 18. Khaliq S, Hameed A, Khaliq T et al (2000) P53 mutations, polymorphisms, and haplotypes in Pakistani ethnie groups and breast cancer patients. Genet Test 4:23-29 (Pubitemid 30217737)
19. Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389-392
20. 20. Li T, Lu ZM, Guo M et al (2002) p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95:2571-2576 (Pubitemid 35424044)
21. 21. Wang-Gohrke S, Becher H, Kreienberg R et al (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12:269-272 (Pubitemid 34596792)
22. Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711-714
23. Huang XE, Hamajima N, Katsuda N et al (2003) Association of p53 codon Arg72Pro and p73 G4C.14-to-A.4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307-311
24. 24. Mabrouk I, Baccouche S, El-Abed R et al (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764-770 (Pubitemid 38265078)
25. 25. Suspitsin EN, Buslov KG, Grigoriev MY et al (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103:431-433 (Pubitemid 36076439)
26. 26. Mahasneh AA, Abdel-Hafiz SS (2004) Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 25: 1568-1573 (Pubitemid 39646625)
27. 27. Noma C, Miyoshi Y, Taguchi T et al (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210: 1.97-203 (Pubitemid 38748690)
28. Kalemi TG, Lambropoulos AF, Gueorguiev M et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57-65
29. 29. Ohayon T, Gershoni-Baruch R, Papa MZ et al (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144-1148 (Pubitemid 40546682)
30. 30. Siddique MM, Balram C, Fiszer-Maliszewska L et al (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14:2245-2252 (Pubitemid 41603274)
31. 31. Tommiska J, Eerola H, Heinonen M. et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103 (Pubitemid 41003693)
32. 32. Damin AP, Frazzon AP, Damin DC et al (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30:523-529 (Pubitemid 44828290)
33. Ma H, Hu Z, Zhai X et al (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766-771
34. 34. Baynes C, Healey CS, Pooley KA et al (2007) Common variants in the ATM, BRCAl, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27 (Pubitemid 350215160)
35. 35. Buyru N, Altinisik J, Demokan S et al (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207-213 (Pubitemid 47248151)
36. 36. Cox DG, Deer D, Guo Q et al (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 18:621-625 (Pubitemid 46883679)
37. Franekova M, Zubor P, Standova A et al (2007) Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma 54:155-161
38. 38. Garcia-Closas M, Kristensen V, Langerod A et al (2007) Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 121:2532-2538 (Pubitemid 350022425)
39. Gochhait S, Bukhari SI, Bairwa N et al (2007) Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res 9:R71
40. Johnson N, Fletcher O, Palles C et al (2007) Counting potentially functional variants in BRCAl, BRCA2 and ATM predicts breast cancer susceptibility. Hum MoI Genet 16:1051-1057
41. 41. Khadang B, Fattahi MJ, Talei A et al (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women, Cancer Genet Cytogenet 1.73:38-42 (Pubitemid 46187296)
42. 42. Pharoah PD, Tyrer J, Dunning AM et al (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42 (Pubitemid 46535758)
43. Samson M, Swaminathan R, Rama R et al (2007) Role of GSTMl (Null/Present), GSTPl (Ile 105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India. Asian Pac J Cancer Prev 8:253-257
44. 44. Schmidt MK, Reincke S, Broeks A et al (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584-9590 (Pubitemid 47535950)
45. 45. Sprague BL, Trentham-Dietz A, Garcia-Closas M. et al (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680-1686 (Pubitemid 47289028)
46. 46. Cavallone L, Arcand SL, Maugard C et al (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins 16, in BRCAl and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96 (Pubitemid 351587049)
47. 47. Costa S, Pinto D, Pereira D et al (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32 (Pubitemid 351314953)
48. De Vecchi G, Verderio P, Pizzamiglio S et al (2008) The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev 32:140-143
49. Gaudet MM, Gammon MD, Bensen JT et al (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 108:93-99
50. 50. Lum SS, Chua HW, Li H et al (2008) MDM2 S.NP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754-761 (Pubitemid 351494162)
51. 51. Nordgard SH, Alnaes GI, Hihn B et al (2008) Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer 123: 577-585 (Pubitemid 351898415)
52. 52. Singh V, Rastogi N, Mathur N et al (2008) Association of polymorphism in M.DM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48-57 (Pubitemid 350184342)
53. 53. Storey A, Thomas M, Kalita A et al (1998) Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature 393:229-234 (Pubitemid 28261713)
54. 54. Damin AP, Karam R, Zettler CG et al (2004) Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat 84:131-137 (Pubitemid 38393363)
55. Akil N, Yasmeen A, Kassab A et al (2008) High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-I expression: a tissue microarray study. Br J Cancer 99:404-407